Concepedia

Author

Edward Agura

Seagen (United States)

Also Known As

E AGURA, E Agura, E. Agura, E.A. Agura, Edward A. Agura, Edward Agura

28

Publications

960

Citations

11

H-Index

12

Concepts

All Affiliations

Seagen (United States)Texas OncologyBaylor University Medical CenterCity Of Hope National Medical CenterUniversity of Utah
EA

About

Edward Agura is an author at Seagen (United States) specializing in cell transplantation, marrow transplantation, and transplantation.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

2

2

119

2

Marrow Transplantation

2

2

119

3

Blood Transplantation

1

1

105

4

Cellular Therapies

1

1

14

5

Immunology

1

1

14

Edward Agura

×

9

Publications

787

Citations

9

H-Index

YearCitations

Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma

Ann S. LaCasce, R. Gregory Bociek, Ahmed Sawas,

Blood

2018

246

Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse

Craig H. Moskowitz, Jan Walewski, Auayporn Nademanee,

Blood

2018

237

The National Marrow Donor Program 20 Years of Unrelated Donor Hematopoietic Cell Transplantation

Karen K. Ballen, Roberta King, Pintip Chitphakdithai,

Biology of Blood and Marrow Transplantation

2008

105

Brentuximab Vedotin Plus Bendamustine: A Highly Active Salvage Treatment Regimen for Patients with Relapsed or Refractory Hodgkin Lymphoma

Ann S. LaCasce, Gregory Bociek, Ahmed Sawas,

Blood

2015

61

Allogeneic blood cell transplantation without posttransplant colony-stimulating factors in patients with hematopoietic neoplasm: a phase II study.

C Rosenfeld, Richard F. Collins, Luis Piñeiro,

Journal of Clinical Oncology

1996

41

Allografting after nonmyeloablative conditioning as a treatment after a failed conventional hematopoietic cell transplant

Lyle Feinstein, Brenda M. Sandmaier, David G. Maloney,

Biology of Blood and Marrow Transplantation

2003

33

Dacetuzumab (SGN-40), Lenalidomide, and Weekly Dexamethasone in Relapsed or Refractory Multiple Myeloma: Multiple Responses Observed in a Phase 1b Study.

Edward Agura, Rubén Niesvizky, Jeffrey Matous,

Blood

2009

33

Updated Efficacy and Safety Data from the AETHERA Trial of Consolidation with Brentuximab Vedotin after Autologous Stem Cell Transplant (ASCT) in Hodgkin Lymphoma Patients at High Risk of Relapse

John Sweetenham, Jan Walewski, Auayporn Nadamanee,

Biology of Blood and Marrow Transplantation

2016

17

LOW DOSE TBI CONDITIONING FOR HEMATOPOIETIC STEM CELL TRANSPLANTS (HSCT) FROM HLA-MATCHED RELATED DONORS FOR PATIENTS WITH HEMATOLOGIC MALIGNANCIES: INFLUENCE OF FLUDARABINE OR CYTOREDUCTIVE AUTOGRAFTS ON OUTCOME

Bm Sandmaier, DG Maloney, TA Gooley,

2002

14

Page 1